Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 single-arm study of tivantinib plus erlotinib in EGFR-mutant NSCLC after EGFR-TKI
jRCT2080221766Phase 2
- Sponsor
- Kyowa Kirin
- Start
- Apr 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tivantinib and erlotinib in non-small cell lung cancer (NSCLC), sponsored by Kyowa Kirin.
02
Drugs
tivantiniberlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2080221766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221766.